Evidence map›Paper›PMID 36168028›Full record

ArticleScientific reports2022

Targeting and ultrabroad insight into molecular basis of Resistance-nodulation-cell division efflux pumps.

Hooria Seyedhosseini Ghaheh, Mohammad Sadegh Damavandi, Parisa Sadeghi, Ahmad Reza Massah, Taravat Hamidi Asl, Azhar Salari-Jazi, Seyed Hossein Hejazi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Occurrence and characterization of plasmids carryingFrontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hooria Seyedhosseini Ghaheh *Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad Sadegh Damavandi *Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Parisa SadeghiDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ahmad Reza MassahDepartment of Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran.
Taravat Hamidi AslSkin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Azhar Salari-JaziDepartment of Drug Development and Innovation, Behban Pharmed Lotus, Tehran, Iran. Azhar_sallari@yahoo.com.
Seyed Hossein HejaziSkin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. hejazi@med.mui.ac.ir.
Isfahan University of Medical Sciences · IRIslamic Azad University of Shahreza · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance-nodulation-cell devision (RND) efflux pump variants have attracted a great deal of attention for efflux of many antibiotic classes, which leads to multidrug-resistant bacteria. The present study aimed to discover the interaction between the RND efflux pumps and antibiotics, find the conserved and hot spot residues, and use this information to target the most frequent RND efflux pumps. Protein sequence and 3D conformational alignments, pharmacophore modeling, molecular docking, and molecular dynamics simulation were used in the first level for discovering the function of the residues in interaction with antibiotics. In the second level, pharmacophore-based screening, structural-based screening, multistep docking, GRID MIF, pharmacokinetic modeling, fragment molecular orbital, and MD simulation were utilized alongside the former level information to find the most proper inhibitors. Five conserved residues, containing Ala209, Tyr404, Leu415, Asp416, and Ala417, as well as their counterparts in other OMPs were evaluated as the crucial conserved residues. MD simulation confirmed that a number of these residues had a key role in the performance of the efflux antibiotics; therefore, some of them were hot spot residues. Fourteen ligands were selected, four of which interacted with all the crucial conserved residues. NPC100251 was the fittest OMP inhibitor after pharmacokinetic computations. The second-level MD simulation and FMO supported the efficacy of the NPC100251. It was exhibited that perhaps OMPs worked as the intelligent and programable protein. NPC100251 was the strongest OMPs inhibitor, and may be a potential therapeutic candidate for MDR infections.

Indexed as

Drug Resistance, Multiple, BacterialMembrane Transport ProteinsAnti-Bacterial AgentsBacterial ProteinsCell DivisionLigandsMolecular Docking SimulationAnti-Bacterial AgentsBacterial ProteinsLigandsMembrane Transport Proteins

Identifiers

PMID36168028
PMCPMC9515154
OpenAlexW4297196226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.